Pemigatinib usage and dosage

Pemigatinib is used in adults to treat cholangiocarcinoma that has spread to other parts of the body (metastasis) or cannot be removed with surgery. Pemigatinib is usually given after the patient has been treated with another drug. Pemetinib is used only if the cancer has a specific genetic marker (an abnormal"FGFR2" gene), which doctors test for. Pemetinib may also be used for purposes not listed in this Medication Guide.

Pemetinib is an inhibitor of FGFR1, 2 and 3. The 13.5 mg dose is taken once daily for 14 days followed by a 7-day break. Food has little effect on absorption. Most of the dose is metabolized by cytochrome P450 (CYP) 3A4 and excreted in the feces. A reduced dose is recommended in patients with severe liver or kidney disease. If CYP3A4 inhibitors such as itraconazole cannot be avoided, dose reduction may also be required.

The original drug Pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).